Abstract
Certain tumour cells, such as gliomas, melanomas and squamous carcinomas has increased numbers of epidermal growth factor receptors per cell, due to gene amplification or increased transcription rates1–3. These receptors could be used as targets for therapy with epidermal growth factor, EGF, conjugated with toxic agents. The numbers of receptors in normal cells are ranging from 0 to 104, but in the mentioned tumour cells the number can be highly increased. Growth factors carrying toxic agents could, due to its size, be better than antibodies at penetrating tumour tissues. The toxic agents could be radioactive nuclides, stable nuclides suitable for neutron capture or toxins. EGF, consisting only a 53 amino acid sequence and a molecular weight of about 6 kDa, has a compact and very stable structure. In earlier studies EGF has been modified without destruction of its biological activity or specificity to the receptor4–6.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
S.H. Bigner, P.C. Burger, A.J. Wong, M.H. Werner, S.R. Hamilton, L.H. Muilbaier, B. Vogelstein, and D.D. Bigner. Gene amplification in malignant human gliomas: clinical and histopathologic aspects. J. Neuropath exp. Neurol. 47: 191–205, 1988.
J. Mendelsohn. Growth factor receptors as targets for anti-tumour therapy with monoclonal antibodies. Monoclonal antibody therapy 45: 147–160, 1988.
V.P. Collins, and C.D. James. Gene and chromosomal alterations associated with the development of human gliomas. F4SEB J. 7: 926–930, 1993.
D.B. Cawley, H.R. Herschman, D.G. Gilliand, and R.J. Collier. Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphteria fragment A is nontoxic. Cell. 22: 563–570, 1980.
A. Andersson, A. Holmberg, J. Carlsson, J. Carlsson, J. Pontén, and B. Westermark. Binding of epidermal growth factor-dextran conjugates to cultured glioma cells. Int. J. Cancer. 47: 439–444, 1991.
P. Olsson, A. Lindström, and J. Carlsson. Internalization and excretion of epidermal growth factor-dextran-associated radioactivity in cultured human squamous-carcinoma cells. Int. J. Cancer: 56: 529–537, 1994.
B. Westermark, A. Magnusson, and C-H. Heldin. Effect of epidermal growth factor on membrane motility and cell locomotion in cultures or human clonal glioma cells. J. tn Neuro.science research. 8: 491–507, 1982.
J. Carlsson, H. Drevin, and R. Axcn. Protein thiolation and reversible protein-protein conjugation. Biochem. J. 173: 723–737, 1978.
A. Holmberg, and L. Meurling. Preparation of sulfhydrylborane-dextran conjugates for boron neutron capture therapy. Bioconfugate chemistry 4: 570–573, 1993.
P. Lindström, P. Olsson, J. Malmqvist, J. Pettersson, P. Lemmen, B. Werner, S. Sjöberg, A. Olin, and J. Carlsson. New carborane-based compounds for boron neutron capture therapy: binding and toxicity of ANC-1, DAC-I and B-Et-I 1-OMe in cultured human glioma and mouse melanoma cells. Anti-Cancer Drugs 5: 43–52, 1994.
T. Hartman, and J. Carlsson. Radiation dose heterogeneous in receptor and antigen mediated boron neutron capture therapy. Radiotherapy and Oncology 31: 61–75, 1994.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gedda, L., Olsson, P., Carlsson, J. (1996). Preparation of Epidermal Growth Factor Conjugates Aimed for Boron Neutron Capture Therapy. In: Mishima, Y. (eds) Cancer Neutron Capture Therapy. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9567-7_3
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9567-7_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9569-1
Online ISBN: 978-1-4757-9567-7
eBook Packages: Springer Book Archive